| Literature DB >> 32095549 |
Shane Minogue1, Charles Gillham2, Maeve Kearney1, Laura Mullaney1.
Abstract
INTRODUCTION: While Computerised Tomography (CT) remains the gold standard in radiation therapy (RT) planning, inferior soft tissue definition remains a challenge. Intravenous contrast (IVC) use during CT planning can enhance soft tissue contrast optimising Target Volume (TV) and Organ at Risk visualisation and delineation. Despite this known benefit, there are no guidelines for when and how to use IVC in RT planning scans in Ireland. AIM: The study aims to examine the patterns of practice in relation to the use of IVC in RT planning scans in Ireland and to determine the level of compliance with international guidelines. Radiation Therapists (RTT) IVC training will also be investigated.Entities:
Keywords: Computerised tomography; Intravenous contrast; Radiation therapists’ practice; Radiation therapy treatment planning scan; Target volume delineation
Year: 2019 PMID: 32095549 PMCID: PMC7033800 DOI: 10.1016/j.tipsro.2019.11.002
Source DB: PubMed Journal: Tech Innov Patient Support Radiat Oncol ISSN: 2405-6324
The UK Royal College of Radiologists guidelines for intravenous contrast use during the radiation therapy planning scan [13].
| UK Royal College of Radiologists tumour sites IVC guidelines | |
|---|---|
| Recommended Tumour Sites | Suggested Tumour Sites |
Pharynx (including nasopharynx; oropharynx and hypopharynx) Nodal disease in the neck from head and neck cancer or other sites Lung Liver Pancreas Stomach Cholangiocarcinoma Oesophagus Kidney | Hodgkin's Disease Non-Hodgkin's Disease Salivary glands Cervix Endometrium/ovary Rectum Larynx Colon Vulva Bladder Adrenal glands |
Recommendations from The Royal Australian and New Zealand College of Radiologists (RANZCR) and The European Society of Urogenital Radiology (ESUR) guidelines on the administration of iodinated contrast.
| RANZCR Guidelines | ESUR Guidelines |
|---|---|
Renal function testing: who and how? | |
| Renal function testing should be assessed if the patient has known kidney disease or presence of diabetes or taking a drug containing metformin | Renal function testing should be assessed if the patient has a known eGFR less than 60 ml/min/1.73 m2 or will receive intra- arterial contrast medium or aged over 70 or at risk of reaction |
| Estimated Glomerular Filtration Rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration proposed equation (CKD-EPI) should be used to assess renal function | |
Risk groups intravenous contrast media related post-contrast acute kidney injury (PC-AKI) | |
| eGFR of less than 45 ml/min/1.73 m2 is a risk factor for PC-AKI | |
| The risk of PC-AKI is likely to be non-existent for patients with eGFR greater than 45 mL/min/1.73 m2 | The risk of PC-AKI with eGFR ≥ 30 ml/min/1.73 m2 is very low |
| Low or non-existent risk for patients with eGFR 30–45 mL/min/1.73 m2 | Preventive measures are recommended for patients with eGFR < 45 ml/min/1.73 m2 if they are in ICU |
| eGFR less than 30 ml/min/1.73 m2 or actively deteriorating renal function the risk versus the benefit should be carefully considered | Preventive measures are recommended for patients with eGFR < 30 ml/min/1.73 m2 before intravenous |
Fig. 1The frequency of intravenous contrast (IVC) usage per department per month.
Fig. 2Usage of intravenous contrast (IVC) for radiation therapy planning scans based on the Royal College Radiologists (RCR) guidelines.
Fig. 3The range of tumour sites (excluding the RCR sites) where intravenous contrast (IVC) is administered during radiation therapy planning scans.
Fig. 4Participants’ response to guideline related questions.